Filgotinib + Placebo to match filgotinib + Prednisone

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Noninfectious Uveitis

Conditions

Noninfectious Uveitis

Trial Timeline

Jul 26, 2017 → Apr 22, 2021

NCT ID

NCT03207815

About Filgotinib + Placebo to match filgotinib + Prednisone

Filgotinib + Placebo to match filgotinib + Prednisone is a phase 2 stage product being developed by Gilead Sciences for Noninfectious Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03207815. Target conditions include Noninfectious Uveitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03207815	Phase 2	Terminated	Jul 26, 2017	Apr 22, 2021	Noninfectious Uveitis

Competing Products

2 competing products in Noninfectious Uveitis

See all competitors

Product	Company	Stage	Hype Score
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
REGN7041	Regeneron Pharmaceuticals	Phase 1/2	39